The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assays
- 15 January 1993
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Preoperative discrimination between ovarian carcinoma, non-ovarian gynecological malignancy and benign adnexal masses using serum levels of CA125 and the polymorphic epithelial mucin antigens CASA, OSA and MSAInternational Journal of Gynecologic Cancer, 1992
- Prognostic significance of tumor ploidy in patients with advanced ovarian carcinomaGynecologic Oncology, 1990
- Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?Gynecologic Oncology, 1990
- Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma—Comparison with CA125Gynecologic Oncology, 1990
- Early serum CA125 response and outcome in epithelial ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Value of serum 125Ca levels: Does the result preclude second look?Gynecologic Oncology, 1989
- Measurement of the ovarian cancer-associated antigen CA 125 prior to second look operationEuropean Journal of Cancer and Clinical Oncology, 1988
- Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapyGynecologic Oncology, 1988
- Independent expression in serum of three tumour-associated antigens: CA 125, placental alkaline phosphatase and HMFG2 in ovarian carcinomaBJOG: An International Journal of Obstetrics and Gynaecology, 1987
- CA125 Serum Levels and Secondary Laparotomy in Epithelial Ovarian TumoursAustralian and New Zealand Journal of Obstetrics and Gynaecology, 1987